Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (761)	1/25/2000 2:34:00 AM
From: Cheryl Galt	Read Replies (1) \| Respond to of 1494

John, I've read most of the articles you cited. I've just begun looking into NTII, prompted primarily by a personal interest in drugs for Diabetic Neuropathy. (Even normal weight, non-smoking, super-well controlled type-2 diabetics can have problems with diabetic neuropathy.) In poking about the web, I found several interesting items. Let me know if anything I post is old hat to the old-timers on this thread. The attached ACT-UP article testifies to the satisfaction of one group of trial patients with memantine -- evidenced by their campaign to maintain access to the drug after the trial ends. It's an old article -- in the Sept 17, 1998 edition of the San Francisco's Bay Area Reporter -- but I think it bodes well for the drug's marketability. One excerpt: " ... Some complications of AIDS are going the way of the dinosaur. The incidence of PCP and KS are way down. This can be attributed to triple combination therapy and prophylactic drugs such as Bactrim or Septra. Other complications however, are becoming more prevalent. Peripheral neuropathy is on the upswing either from drug toxicity or from HIV disease itself. People with AIDS want relief from the numbness and pain of neuropathy.... " actupgg.org The relevant section is "ACTG 301 - an ongoing study of Memantine for AIDS dementia."